<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>332</serviceExecutionTime><Drug id="3290"><DrugName>Hoe-694</DrugName><DrugSynonyms><Name><Value>Hoe-694</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>149725-40-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="16807">Hoechst AG</CompanyOriginator><CompaniesSecondary><Company id="16807">Hoechst AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="3290" type="Drug"><TargetEntity id="189238" type="siDrug">Hoe-694</TargetEntity></SourceEntity><SourceEntity id="16807" type="Company"><TargetEntity id="5035555553" type="organizationId">Hoechst AG</TargetEntity></SourceEntity><SourceEntity id="224" type="ciIndication"><TargetEntity id="10028596" type="MEDDRA"></TargetEntity><TargetEntity id="D009203" type="MeSH"></TargetEntity><TargetEntity id="-998451372" type="omicsDisease"></TargetEntity><TargetEntity id="226" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="27" type="ciIndication"><TargetEntity id="10003119" type="MEDDRA"></TargetEntity><TargetEntity id="D001145" type="MeSH"></TargetEntity><TargetEntity id="-100431042" type="omicsDisease"></TargetEntity><TargetEntity id="189" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2623" type="Action"><TargetEntity id="837" type="Mechanism">Na+/H+ Exchanger (NHE) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="498" type="Action"><TargetEntity id="358" type="Mechanism">Sodium Channel Blockers</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><IndicationsSecondary><Indication id="224">Myocardial infarction</Indication><Indication id="27">Heart arrhythmia</Indication></IndicationsSecondary><ActionsPrimary><Action id="2623">Sodium hydrogen exchanger inhibitor</Action><Action id="498">Sodium channel inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="65">Class I antiarrhythmic agent</Action><Action id="2659">Cardioprotectant</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C1B</Code><Name>ANTI-ARRHYTHMICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-18T13:40:34.000Z</LastModificationDate><ChangeDateLast>2011-01-27T18:22:04.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="16807" linkType="Company"&gt;Hoechst AG&lt;/ulink&gt; was developing HOE-694, a sodium channel blocker, for the potential treatment of arrhythmia and myocardial infarction. The drug was in phase I trials for arrhythmia and myocardial infarction before being dropped in favour of &lt;ulink linkID="8718" linkType="Drug"&gt;cariporide&lt;/ulink&gt; (HOE-642) [&lt;ulink linkID="226741" linkType="reference"&gt;226741&lt;/ulink&gt;]. The compound is widely used as a pharmacological tool in studies requiring selective Na+/H+-exchange inhibition. It is a specific inhibitor of the NHE-1 isoform of the Na+/H+ exchangers [&lt;ulink linkID="253616" linkType="reference"&gt;253616&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><ExpertReview>&lt;para&gt;Martin P Kelly, Division of Clinical Pharmacology and Alyson L Huntley, Department of Child Health, Leicester Royal Infirmary, &lt;ulink linkType="Company" linkID="22496"&gt;University of Leicester&lt;/ulink&gt;, Leicester, UK&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;30 October 1997&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;HOE-642 (&lt;ulink linkType="Drug" linkID="8718"&gt;cariporide&lt;/ulink&gt;) and &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; are both potent, specific inhibitors of the sodium/hydrogen exchanger isoform 1 (NHE-1) [&lt;ulink linkType="reference" linkID="253616"&gt;253616&lt;/ulink&gt;]. The compounds were both in development by Hoechst Marion Roussel until recently, but &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; was dropped in favor of HOE-642 [&lt;ulink linkType="reference" linkID="226741"&gt;226741&lt;/ulink&gt;]. HOE-642 is now in phase III clinical trials as an anti-ischemic and antiarrhythmic. Sodium/hydrogen exchange in the myocardium during both ischemia and reperfusion events is thought to lead to cardiac arrhythmias and tissue death [&lt;ulink linkType="reference" linkID="173338"&gt;173338&lt;/ulink&gt;]. This may be due to intracellular sodium overload [&lt;ulink linkType="reference" linkID="154139"&gt;154139&lt;/ulink&gt;], an increase in intracellular calcium [&lt;ulink linkType="reference" linkID="159802"&gt;159802&lt;/ulink&gt;] and increased lactic acid production [&lt;ulink linkType="reference" linkID="173338"&gt;173338&lt;/ulink&gt;]. The development of inhibitors of sodium/hydrogen exchange may therefore lead to a new therapeutic approach in clinical indications related to cardiac ischemia and reperfusion. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;HOE-642 and &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; are benzoylguanidines [&lt;ulink linkType="reference" linkID="186936"&gt;186936&lt;/ulink&gt;]. In vitro studies using mutated NHE-1, showed that the putative ninth transmembrane domain (M9) is the major site of interaction of both HOE-642 and &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="223434"&gt;223434&lt;/ulink&gt;]. M9 was also found to be the major binding site for &lt;ulink linkType="Drug" linkID="44398"&gt;cimetidine&lt;/ulink&gt; and 5-amino substituted analogs of amiloride, eg, ethylisopropyl amiloride (EIPA). A substituent in the 2-position, relative to the acylguanidine is of crucial importance for the potency of HOE-642 and &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="253616"&gt;253616&lt;/ulink&gt;]. Synthetic pathways for the two compounds have been described [&lt;ulink linkType="reference" linkID="247747"&gt;247747&lt;/ulink&gt;]. It is important to note that whilst compounds like HOE-642 and &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; show high specificity and efficacy in experimental models, 2-methyl substituted compounds, such as 2-methyl-5-methylsulfonyl-4-pyrrolobenzoyl-guanidine methanesulfonate, may show higher specificity, whilst retaining a similar clinical efficacy [&lt;ulink linkType="reference" linkID="253616"&gt;253616&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;HOE-642 concentration-dependently inhibits amiloride-sensitive sodium influx in rabbit erythrocytes, reduces swelling in human platelets induced by intracellular acidification, and delays pH recovery in rat cardiomyocytes [&lt;ulink linkType="reference" linkID="173338"&gt;173338&lt;/ulink&gt;]. Similarly, &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; inhibits sodium/hydrogen exchange in rabbit erythrocytes, rat platelets and bovine endothelial cells [&lt;ulink linkType="reference" linkID="161109"&gt;161109&lt;/ulink&gt;]. The potency of &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; is comparable to EIPA in these models. In mutant fibroblast cell lines expressing sodium/hydrogen exchanger isoforms, &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; discriminates between NHE-1 and other isoforms with a much greater specificity than amiloride or its 5-amino substituted analogs [&lt;ulink linkType="reference" linkID="163989"&gt;163989&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In isolated working rat hearts subjected to ischemia and reperfusion, HOE-642 dose-dependently reduces the incidence and duration of reperfusion arrhythmias [&lt;ulink linkType="reference" linkID="173338"&gt;173338&lt;/ulink&gt;] compared to controls. It also reduces the release of lactate dehydrogenase and creatinine kinase, and preserves the tissue content of glycogen, creatine phosphate and ATP. Similar results are obtained when &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; is administered to isolated rabbit hearts, subjected to ischemic arrest and reperfusion [&lt;ulink linkType="reference" linkID="218160"&gt;218160&lt;/ulink&gt;]. In a pig model of experimentally-induced cardiac ischemia and reperfusion injury, &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; (7 mg/kg bolus and 0.07 mg/kg infusion) improves regional wall function and eliminates ventricular fibrillation [&lt;ulink linkType="reference" linkID="154139"&gt;154139&lt;/ulink&gt;]. Ultrastructural morphology after ischemia and reperfusion is near normal in treated animals. In similar experiments using HOE-642 (1 mg/kg, iv), the occurrence of fatal ventricular fibrillation in dogs is significantly reduced [&lt;ulink linkType="reference" linkID="241178"&gt;241178&lt;/ulink&gt;]. The duration and incidence of ventricular tachycardia and fatal reperfusion-induced ventricular fibrillation in rats is also reduced [&lt;ulink linkType="reference" linkID="241178"&gt;241178&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In rabbits, administration of HOE-642 (0.6 mg/kg) before induction of ischemia limits infarct size by about 50% compared to matched controls [&lt;ulink linkType="reference" linkID="263289"&gt;263289&lt;/ulink&gt;]. However, injection of HOE-642 before reperfusion does not change infarct size. In pigs, administration of &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; before induction of ischemia reduces the size of the resultant infarction by about 95% [&lt;ulink linkType="reference" linkID="263322"&gt;263322&lt;/ulink&gt;] compared to controls. Treatment with &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; before reperfusion also reduces infarct size to around 50%.&lt;/para&gt;&lt;para&gt;Sodium/hydrogen exchange is a major mechanism for restoration of intracellular pH after ischemia, although its activation during both ischemia and reperfusion has been shown to be involved in a paradoxical induction of cell injury [&lt;ulink linkType="reference" linkID="173338"&gt;173338&lt;/ulink&gt;]. This probably reflects the fact that activation of the exchanger is closely coupled to sodium influx and, consequently, an elevation in intracellular calcium concentrations due to activation of the sodium/calcium exchanger [&lt;ulink linkType="reference" linkID="159802"&gt;159802&lt;/ulink&gt;]. This elevated calcium inevitably leads to contractile dysfunction. Since in vivo animal ischemia/reperfusion arrhythmia models mimic clinical myocardial infarction, intracoronary thrombolysis or angioplasty, it may expected that this class of sodium/hydrogen exchange inhibitors may produce effective antiarrhythmic drugs.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;In dose-response studies with rabbit erythrocytes, &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; had an IC50 of 1 microM [&lt;ulink linkType="reference" linkID="161109"&gt;161109&lt;/ulink&gt;]. Similarly, the IC50 for HOE-642 was 0.1 - 1 microM in rabbit erythrocytes, human platelets and rat cardiomyocytes [&lt;ulink linkType="reference" linkID="173338"&gt;173338&lt;/ulink&gt;]. In studies conducted in pigs, a bolus injection of &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; (7 mg/kg, iv) followed by continuous infusion (0.07 mg/kg/min, iv) [&lt;ulink linkType="reference" linkID="154139"&gt;154139&lt;/ulink&gt;] or infusion alone (7 mg/kg/15 mins, iv) [&lt;ulink linkType="reference" linkID="263322"&gt;263322&lt;/ulink&gt;] did not affect either hemodynamic parameters or cardiac contractility. Plasma levels of &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; were around 10 microM, enough to inhibit sodium/hydrogen exchange. In similar studies in dogs and rats [&lt;ulink linkType="reference" linkID="241178"&gt;241178&lt;/ulink&gt;], where HOE-642 was given as a bolus injection (1 mg/kg, iv), the hemodynamic status was unaffected. Plasma concentrations of HOE-642 in the treated dogs were in the range of 0.7 - 6.9 microM and therefore sufficient to inhibit sodium/hydrogen exchange. These data suggest that HOE-642 and &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; are able to exert their cardioprotective effect without an effect on the hemodynamic profile, giving them a tremendous potential advantage over established modulators of cardiovascular function. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No toxic effects have been reported for either HOE-642 or &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; reached phase I clinical trials as an antiarrhythmic and potential treatment for myocardial infarction before being dropped in favor of &lt;ulink linkType="Drug" linkID="8718"&gt;cariporide&lt;/ulink&gt; (HOE-642) [&lt;ulink linkType="reference" linkID="226741"&gt;226741&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;A trial for &lt;ulink linkType="Drug" linkID="8718"&gt;cariporide&lt;/ulink&gt; (HOE-642) involving 9000 patients is already underway. Results are not yet available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;The above trial is passing into phase III, with EU and US approval, filings are expected to be lodged in 1998.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side-effects and Contraindications&lt;/subtitle&gt;No adverse reactions have been reported for either HOE-642 or &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt;. Neither compound has detectable inhibitory potency for pH-regulating carriers in the heart other than NHE-1 [&lt;ulink linkType="reference" linkID="223438"&gt;223438&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="173338"&gt;173338&lt;/ulink&gt;]. HOE-642 and &lt;ulink linkType="Drug" linkID="3290"&gt;HOE-694&lt;/ulink&gt; also have specific advantages over amiloride derivatives, such as EIPA, which inhibit both NHE-1 and NHE-3 [&lt;ulink linkType="reference" linkID="256453"&gt;256453&lt;/ulink&gt;] and are sodium-displacing, making their clinical potential limited.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Sodium/hydrogen exchange is an important target for pharmacological intervention in the attenuation of ischemia and reperfusion-induced cardiac injury. &lt;ulink linkType="Drug" linkID="8718"&gt;Cariporide&lt;/ulink&gt; (HOE-642) has been designated as one of Hoechst Marion Roussel's nine top priority products, with a potential market in excess of $500 million per year [&lt;ulink linkType="reference" linkID="221118"&gt;221118&lt;/ulink&gt;]. It is the only drug of its class currently in development. It is an extremely promising alternative to other classes of drugs for the treatment of arrhythmias and ischemic heart disease, given its apparent lack of side-effects and contraindications. Whilst there is there is good in vitro, ex-vivo and animal model evidence for the specificity, inhibitory action and clinical action of this class of sodium/hydrogen exchange inhibitor, published data in human subjects is lacking. The progression of &lt;ulink linkType="Drug" linkID="8718"&gt;cariporide&lt;/ulink&gt; to the market will therefore depend on its efficacy in the imminent phase III clinical trials.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="16807">Hoechst AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="27">Heart arrhythmia</Indication><StatusDate>1996-12-31T00:00:00.000Z</StatusDate><Source id="226741" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16807">Hoechst AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="224">Myocardial infarction</Indication><StatusDate>1996-12-31T00:00:00.000Z</StatusDate><Source id="226741" type="SERIAL"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><Targets><Target id="PTGT-01378"><Name>Sodium hydrogen exchanger</Name><SwissprotNumbers><Swissprot>O14123</Swissprot><Swissprot>O42701</Swissprot><Swissprot>Q04121</Swissprot><Swissprot>Q58671</Swissprot><Swissprot>Q58916</Swissprot><Swissprot>Q60362</Swissprot><Swissprot>Q99173</Swissprot><Swissprot>Q99271</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01747"><Name>Sodium channel</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CS(=O)(=O)c1cc(ccc1N2CCCCC2)C(=O)N=C(N)N.CS(=O)(=O)O</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="346326" number="WO-00224637" title="Substituted cinnamic acid guanidides, method for the production thereof, their use as a medicament, and to a medicament containing these compounds"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>